levonorgestrel-releasing intrauterine system (Mirena, LNG-IUS, LILETTA, Skyla)
Jump to navigation
Jump to search
Indications
- contraception*
- abnormal uterine bleeding#
* appropriate contraceptive option for women at increased risk for venous thromboemboembolism[4]
* appropriate contraceptive option for women with uncontrolled hypertension[6]
# FDA approved in US only for contraception; however, it is the most effective hormonal treatment for abnormal uterine bleeding.
Procedure
Notes
- LILETTA FDA-approved for use by women to prevent pregnancy for up to three years[2]
- Mirena IUS is now U.S. FDA approved for preventing pregnancy for 8 years[5]
More general terms
References
- ↑ Journal Watch 24(9):69, 2004 Hurskainen R, Teperi J, Rissanen P, Aalto AM, Grenman S, Kivela A, Kujansuu E, Vuorma S, Yliskoski M, Paavonen J. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA. 2004 Mar 24;291(12):1456-63. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15039412
- ↑ 2.0 2.1 Actavis and Medicines360 Announce FDA Approval of LILETTA (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Three Years.
- ↑ FDA Approves Additional Use for IUD Mirena to Treat Heavy Menstrual Bleeding in IUD Users
- ↑ 4.0 4.1 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
- ↑ 5.0 5.1 Jensen JT et al. Contraceptive efficacy and safety of 52mg LNG-IUS for up to 8 years: Findings from the Mirena Extension Trial. Am J Obstet Gynecol 2022 Sep 9; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36096186 https://www.ajog.org/article/S0002-9378(22)00729-3/pdf
- ↑ 6.0 6.1 NEJM Knowledge+